Population pharmacokinetics of posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome

References

• Lin SJ, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis 2001;32:358-66
   PubMed Web of Science ®Google Scholar
• von Eiff M, Roos N, Schulten R, et al. Pulmonary aspergillosis: early diagnosis improves survival. Respiration 1995;62:341-7
   PubMed Web of Science ®Google Scholar
• Roden MM, Zaoutis TE, Buchanan WL, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis 2005;41:634-53
   PubMed Web of Science ®Google Scholar
• Viscoli C, Girmenia C, Marinus A, et al. Candidemia in cancer patients: a prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC). Clin Infect Dis 1999;28:1071-9
   PubMed Web of Science ®Google Scholar
• Ascioglu S, Rex JH, de Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002;34:7-14
   PubMed Web of Science ®Google Scholar
• Prentice HG, Kibbler CC, Prentice AG. Towards a targeted, risk-based, antifungal strategy in neutropenic patients. Br J Haematol 2000;110:273-84
   PubMed Web of Science ®Google Scholar
• Sabatelli F, Patel R, Mann PA, et al. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob Agents Chemother 2006;50:2009-15
   PubMed Web of Science ®Google Scholar
• Greenberg RN, Mullane K, van Burik J-AH, et al. Posaconazole as salvage therapy for zygomycosis. Antimicrob Agents Chemother 2006;50:126-33
   PubMed Web of Science ®Google Scholar
• van Burik J-AH, Hare RS, Solomon HF, et al. Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin Infect Dis 2006;42:e61-e65
   PubMed Web of Science ®Google Scholar
• Raad II, Hachem RY, Herbrecht R, et al. Posaconazole as salvage treatment of invasive fusariosis in patients with underlying hematologic malignancy and other conditions. Clin Infect Dis 2006;42:1398-403
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Raad I, Patterson TF, et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis 2007;44:2-12
   PubMed Web of Science ®Google Scholar
• Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007;356:335-47
   PubMed Web of Science ®Google Scholar
• Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007;356:348-59
   PubMed Web of Science ®Google Scholar
• Krishna G, Tarif MA, Xuan F, et al. Pharmacokinetics of oral posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome. Pharmacotherapy 2008;28:1223-32
   PubMed Web of Science ®Google Scholar
• Courtney R, Pai S, Laughlin M, et al. Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults. Antimicrob Agents Chemother 2003;47:2788-95
   PubMed Web of Science ®Google Scholar
• Camilleri M. Diabetic gastroparesis. N Engl J Med 2007;356:820-9
   PubMed Web of Science ®Google Scholar
• Gubbins PO, Krishna G, Sansone-Parsons A, et al. Pharmacokinetics and safety of oral posaconazole in neutropenic stem cell transplant recipients. Antimicrob Agents Chemother 2006;50:1993-9
   PubMed Web of Science ®Google Scholar
• Krishna G, Wexler D, Shah A, et al. The pharmacokinetics of oral posaconazole in recipients of allogeneic hematopoietic stem cell transplantation with graft-versus-host disease. Pharmacotherapy 2007;27:1627-36
   PubMed Web of Science ®Google Scholar
• Courtney R, Wexler D, Radwanski E, et al. Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults. Br J Clin Pharmacol 2003;57:218-22
   Web of Science ®Google Scholar
• Ezzet F, Wexler D, Courtney R, et al. Oral bioavailability of posaconazole in fasted healthy subjects: comparison between three regimens and basis for clinical dosage recommendations. Clin Pharmacokinet 2005;44:211-20
   PubMed Web of Science ®Google Scholar
• Krishna G, Sansone-Parsons A. Pharmacokinetics of posaconazole in healthy volunteers: a meta-analysis of five phase 1 studies. Presented at: 41st American Society of Health-System Pharmacists Midyear Clinical Meeting and Exhibition December 3–7, 2006 Anaheim, CA
   Google Scholar
• Sansone-Parsons A, Krishna G, Simon J, et al. Effects of age, gender, and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers. Antimicrob Agents Chemother 2007;51:495-502
   PubMed Web of Science ®Google Scholar
• Courtney R, Martinho M, Lim J, et al. Evaluation of the effect of age, weight, race, and gender on posaconazole plasma concentrations in HIV-infected patients. Presented at: 13th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) May 10–13, 2003, Glasgow, Scotland, UK
   Google Scholar
• Shen JX, Krishna G, Hayes RN. A sensitive liquid chromatography and mass spectrometry method for the determination of posaconazole in human plasma. J Pharm Biomed Anal 2007;43:228-36
   PubMed Web of Science ®Google Scholar
• Beal SL, Sheiner LB. NONMEM users’ guides. San Francisco: NONMEM Project Group, University of California, San Francisco, 1992
   Google Scholar
• Wahlby U, Jonsson EN, Karlsson MO. Comparison of stepwise covariate model building strategies in population pharmacokinetic-pharmacodynamic analysis. AAPS Pharm Sci 2002;4:E27
   PubMedGoogle Scholar
• Jonsson EN, Karlsson MO. Automated covariate model building within NONMEM. Pharm Res 1998;15:1463-8
   PubMed Web of Science ®Google Scholar
• Jen J, Laughlin M, Chung C, et al. Ribavirin dosing in chronic hepatitis C: application of population pharmacokinetic-pharmacodynamic models. Clin Pharmacol Ther 2002;72:349-61
   PubMed Web of Science ®Google Scholar
• Guidance for industry: population pharmacokinetics. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, and Center for Biologics Evaluation and Research. Available at: www.fda.gov/cder/guidance/1852pk.htm [Last accessed 20 October 2008]
   Google Scholar
• Ette EI. Stability and performance of a population pharmacokinetic model. J Clin Pharmacol 1997;37:486-95
   PubMed Web of Science ®Google Scholar
• Podolsky DK, Isselbacher KJ. Diagnostic tests in liver disease. In: Isselbacher KJ, Braunwald E, Wilson JD, et al. (eds.) Harrison’s Principles of Internal Medicine, 13th edn. New York, NY: McGraw Hill, 1994
   Google Scholar